Roche Reports Positive Study of RoACTEMRA

Roche announced that the SUMMACTA study met its primary endpoint. Data from SUMMACTA will be submitted for presentation at an upcoming medical meeting.

Roche announced that the SUMMACTA study met its primary endpoint, showing comparable efficacy of the subcutaneous (SC) formulation of RoACTEMRA (tocilizumab, known as ACTEMRA outside Europe) 162mg weekly compared to 8 mg/kg RoACTEMRA intravenous (IV) formulation every 4 weeks.

A similar proportion of rheumatoid arthritis (RA) patients in each group achieved an ACR20 response at Week 24, a measure indicating improvement in the number of tender and swollen joints, pain scale, patients’ and physicians’ assessment of improvement and certain laboratory markers.

Preliminary safety analysis showed that the adverse event profiles of the SC and IV groups were comparable, with no new clinically meaningful safety signals identified.